Benchmark Capital Advisors boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 167.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,008 shares of the medical research company’s stock after buying an additional 2,508 shares during the period. Benchmark Capital Advisors’ holdings in Amgen were worth $610,000 as of its most recent SEC filing.
A number of other hedge funds have also recently added to or reduced their stakes in the stock. Schwartz Investment Counsel Inc. raised its stake in Amgen by 2.3% in the second quarter. Schwartz Investment Counsel Inc. now owns 222,750 shares of the medical research company’s stock valued at $33,891,000 after buying an additional 5,000 shares in the last quarter. Brown Advisory Inc. raised its stake in Amgen by 4.1% in the second quarter. Brown Advisory Inc. now owns 162,780 shares of the medical research company’s stock valued at $24,768,000 after buying an additional 6,353 shares in the last quarter. Pittenger & Anderson Inc. raised its stake in Amgen by 39.2% in the second quarter. Pittenger & Anderson Inc. now owns 22,230 shares of the medical research company’s stock valued at $3,382,000 after buying an additional 6,255 shares in the last quarter. Prudential Financial Inc. raised its stake in Amgen by 4.8% in the second quarter. Prudential Financial Inc. now owns 2,251,000 shares of the medical research company’s stock valued at $342,490,000 after buying an additional 103,083 shares in the last quarter. Finally, Private Advisor Group LLC raised its stake in Amgen by 32.8% in the second quarter. Private Advisor Group LLC now owns 33,312 shares of the medical research company’s stock valued at $5,084,000 after buying an additional 8,232 shares in the last quarter. Institutional investors own 79.15% of the company’s stock.
Shares of Amgen Inc. (NASDAQ:AMGN) traded down 0.60% on Thursday, hitting $168.70. 655,038 shares of the company were exchanged. The company has a 50-day moving average price of $172.00 and a 200 day moving average price of $160.83. The firm has a market cap of $126.25 billion, a P/E ratio of 17.26 and a beta of 0.87. Amgen Inc. has a 52-week low of $135.64 and a 52-week high of $176.85.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, beating the Zacks’ consensus estimate of $2.74 by $0.10. The firm had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.58 billion. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The firm’s revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the company earned $2.57 EPS. Analysts predict that Amgen Inc. will post $11.36 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Wednesday, August 17th were paid a dividend of $1.00 per share. The ex-dividend date of this dividend was Monday, August 15th. This represents a $4.00 annualized dividend and a dividend yield of 2.36%. Amgen’s dividend payout ratio is currently 40.90%.
Several research firms recently commented on AMGN. Jefferies Group restated a “buy” rating on shares of Amgen in a research report on Wednesday. Citigroup Inc. dropped their price target on shares of Amgen from $175.00 to $172.00 and set a “neutral” rating on the stock in a research report on Wednesday. JPMorgan Chase & Co. restated a “hold” rating on shares of Amgen in a research report on Wednesday. Goldman Sachs Group Inc. restated a “buy” rating and set a $206.00 price target (up previously from $204.00) on shares of Amgen in a research report on Tuesday. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $190.00 target price on shares of Amgen in a research report on Thursday, September 22nd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $184.51.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total transaction of $523,770.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.20% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.